vs

Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and OPEN TEXT CORP (OTEX). Click either name above to swap in a different company.

OPEN TEXT CORP is the larger business by last-quarter revenue ($1.3B vs $766.2M, roughly 1.7× BIOMARIN PHARMACEUTICAL INC). BIOMARIN PHARMACEUTICAL INC runs the higher net margin — 13.8% vs 13.5%, a 0.4% gap on every dollar of revenue. On growth, BIOMARIN PHARMACEUTICAL INC posted the faster year-over-year revenue change (3.0% vs 2.2%). Over the past eight quarters, BIOMARIN PHARMACEUTICAL INC's revenue compounded faster (3.7% CAGR vs -3.0%).

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Open Text Corporation is a global software company that develops and sells information management software.

BMRN vs OTEX — Head-to-Head

Bigger by revenue
OTEX
OTEX
1.7× larger
OTEX
$1.3B
$766.2M
BMRN
Growing faster (revenue YoY)
BMRN
BMRN
+0.8% gap
BMRN
3.0%
2.2%
OTEX
Higher net margin
BMRN
BMRN
0.4% more per $
BMRN
13.8%
13.5%
OTEX
Faster 2-yr revenue CAGR
BMRN
BMRN
Annualised
BMRN
3.7%
-3.0%
OTEX

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BMRN
BMRN
OTEX
OTEX
Revenue
$766.2M
$1.3B
Net Profit
$106.0M
$172.7M
Gross Margin
74.6%
73.1%
Operating Margin
16.9%
15.7%
Net Margin
13.8%
13.5%
Revenue YoY
3.0%
2.2%
Net Profit YoY
EPS (diluted)
$0.54
$0.70

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMRN
BMRN
OTEX
OTEX
Q1 26
$766.2M
$1.3B
Q4 25
$874.6M
$1.3B
Q3 25
$776.1M
$1.3B
Q2 25
$825.4M
$1.3B
Q1 25
$745.1M
$1.3B
Q4 24
$747.3M
$1.3B
Q3 24
$745.7M
$1.3B
Q2 24
$712.0M
$1.4B
Net Profit
BMRN
BMRN
OTEX
OTEX
Q1 26
$106.0M
$172.7M
Q4 25
$-46.6M
$168.1M
Q3 25
$-30.7M
$146.6M
Q2 25
$240.5M
$28.8M
Q1 25
$185.7M
$92.8M
Q4 24
$124.9M
$229.9M
Q3 24
$106.1M
$84.4M
Q2 24
$107.2M
$248.2M
Gross Margin
BMRN
BMRN
OTEX
OTEX
Q1 26
74.6%
73.1%
Q4 25
68.5%
74.0%
Q3 25
82.0%
72.8%
Q2 25
81.8%
72.3%
Q1 25
79.7%
71.6%
Q4 24
81.8%
73.3%
Q3 24
74.7%
71.7%
Q2 24
81.7%
72.5%
Operating Margin
BMRN
BMRN
OTEX
OTEX
Q1 26
16.9%
15.7%
Q4 25
-5.1%
22.0%
Q3 25
-6.0%
21.0%
Q2 25
33.5%
13.9%
Q1 25
30.0%
16.7%
Q4 24
21.6%
22.2%
Q3 24
15.3%
16.3%
Q2 24
16.9%
14.2%
Net Margin
BMRN
BMRN
OTEX
OTEX
Q1 26
13.8%
13.5%
Q4 25
-5.3%
12.7%
Q3 25
-4.0%
11.4%
Q2 25
29.1%
2.2%
Q1 25
24.9%
7.4%
Q4 24
16.7%
17.2%
Q3 24
14.2%
6.6%
Q2 24
15.1%
18.2%
EPS (diluted)
BMRN
BMRN
OTEX
OTEX
Q1 26
$0.54
$0.70
Q4 25
$-0.22
$0.66
Q3 25
$-0.16
$0.58
Q2 25
$1.23
$0.11
Q1 25
$0.95
$0.35
Q4 24
$0.65
$0.87
Q3 24
$0.55
$0.32
Q2 24
$0.55
$0.91

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMRN
BMRN
OTEX
OTEX
Cash + ST InvestmentsLiquidity on hand
$2.2B
$1.3B
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$6.2B
$4.0B
Total Assets
$8.6B
$13.3B
Debt / EquityLower = less leverage
1.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMRN
BMRN
OTEX
OTEX
Q1 26
$2.2B
$1.3B
Q4 25
$1.3B
$1.3B
Q3 25
$1.3B
$1.1B
Q2 25
$1.2B
$1.2B
Q1 25
$1.0B
$1.3B
Q4 24
$942.8M
$1.1B
Q3 24
$675.4M
$1.0B
Q2 24
$972.1M
$1.3B
Total Debt
BMRN
BMRN
OTEX
OTEX
Q1 26
$6.2B
Q4 25
$6.4B
Q3 25
$6.4B
Q2 25
$6.4B
Q1 25
$6.4B
Q4 24
$6.4B
Q3 24
$6.4B
Q2 24
$6.4B
Stockholders' Equity
BMRN
BMRN
OTEX
OTEX
Q1 26
$6.2B
$4.0B
Q4 25
$6.1B
$4.0B
Q3 25
$6.1B
$4.0B
Q2 25
$6.0B
$3.9B
Q1 25
$5.8B
$4.1B
Q4 24
$5.7B
$4.2B
Q3 24
$5.4B
$4.1B
Q2 24
$5.3B
$4.2B
Total Assets
BMRN
BMRN
OTEX
OTEX
Q1 26
$8.6B
$13.3B
Q4 25
$7.6B
$13.6B
Q3 25
$7.6B
$13.5B
Q2 25
$7.5B
$13.8B
Q1 25
$7.1B
$13.8B
Q4 24
$7.0B
$13.7B
Q3 24
$6.9B
$13.8B
Q2 24
$7.1B
$14.2B
Debt / Equity
BMRN
BMRN
OTEX
OTEX
Q1 26
1.57×
Q4 25
1.58×
Q3 25
1.61×
Q2 25
1.62×
Q1 25
1.55×
Q4 24
1.51×
Q3 24
1.55×
Q2 24
1.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMRN
BMRN
OTEX
OTEX
Operating Cash FlowLast quarter
$220.7M
$354.6M
Free Cash FlowOCF − Capex
$305.0M
FCF MarginFCF / Revenue
23.8%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
2.08×
2.05×
TTM Free Cash FlowTrailing 4 quarters
$809.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMRN
BMRN
OTEX
OTEX
Q1 26
$220.7M
$354.6M
Q4 25
$99.6M
$318.7M
Q3 25
$368.7M
$147.8M
Q2 25
$185.3M
$158.2M
Q1 25
$174.4M
$402.2M
Q4 24
$185.6M
$348.0M
Q3 24
$221.5M
$-77.8M
Q2 24
$118.8M
$185.2M
Free Cash Flow
BMRN
BMRN
OTEX
OTEX
Q1 26
$305.0M
Q4 25
$58.9M
$279.4M
Q3 25
$340.2M
$101.2M
Q2 25
$168.2M
$124.0M
Q1 25
$157.6M
$373.8M
Q4 24
$166.1M
$306.7M
Q3 24
$203.0M
$-117.1M
Q2 24
$97.4M
$145.2M
FCF Margin
BMRN
BMRN
OTEX
OTEX
Q1 26
23.8%
Q4 25
6.7%
21.1%
Q3 25
43.8%
7.9%
Q2 25
20.4%
9.5%
Q1 25
21.2%
29.8%
Q4 24
22.2%
23.0%
Q3 24
27.2%
-9.2%
Q2 24
13.7%
10.7%
Capex Intensity
BMRN
BMRN
OTEX
OTEX
Q1 26
3.9%
Q4 25
4.7%
3.0%
Q3 25
3.7%
3.6%
Q2 25
2.1%
2.6%
Q1 25
2.3%
2.3%
Q4 24
2.6%
3.1%
Q3 24
2.5%
3.1%
Q2 24
3.0%
2.9%
Cash Conversion
BMRN
BMRN
OTEX
OTEX
Q1 26
2.08×
2.05×
Q4 25
1.90×
Q3 25
1.01×
Q2 25
0.77×
5.49×
Q1 25
0.94×
4.33×
Q4 24
1.49×
1.51×
Q3 24
2.09×
-0.92×
Q2 24
1.11×
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMRN
BMRN

Segment breakdown not available.

OTEX
OTEX

Customer support$564.8M44%
Cloud services and subscriptions$492.9M38%
License$145.1M11%
Professional service and other$79.6M6%

Related Comparisons